Non-alcoholic fatty liver disease (NAFLD) is a scourge of the planet's population, especially the developed countries. NAFLD development is due to the global increase in the number of overweight and obese people. NAFLD in its turn is the main factor of cardiovascular risk development. Early detection of the cardiovascular risk development with underlying NAFLD and overweight remains understudied. This article reviews the literature dealing with the diagnosis and treatment of NAFLD in overweight subjects.
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(CAD), and cholelithiasis. The majority of patients are females (65-85%) with a mean age of 50 years old. In most cases, BMI is greater than 25 kg/m². Clinical symptoms are absent in 50-100% with the most common ones being asthenic syndrome, abdominal discomfort, and heaviness in the right subcostal area [12] .
The generalizing NAFLD pathogenesis model was previously believed to be the "theory of two hits", according to which the "first hit" is an increased influx of free fatty acids (FFA) in the liver. The accumulation of fat in hepatocytes is a consequence of FFAs coming from the fatty tissue, their slower oxidation in mitochondria and excessive synthesis of FFAs from acetyl coenzyme А. The increased influx of FFAs and their slower oxidation lead to FFA esterification with excessive formation of triglycerides in hepatocytes and excessive secretion of very-low-density lipoprotein cholesterol (VLDLP CS), which enhances freeradical oxidation of lipids and accumulation of the peroxidation products ("second hit") [13] . Thus, the liver is a target organ in this case; hepatomegaly in patients with overweight or abdominal obesity (AO) is due to the accumulation of fat on account of its expansion from natural sources and to the fact that the hepatocyte apoptosis rate is lower than the proliferation rate [14] .
Fibrosis is a result of the steatohepatitis transformation through the merging of fat deposits during hepatocyte breaking with the formation of cysts, inflow of a large amount of lipids from hepatocytes to the interstitial region with an inflammatory reaction and fibrotic changes, mechanical and inflammatory damage of hepatic veins and development of perivenular fibrosis. The development of hepatic cirrhosis is due to the obstruction of hepatic veins, ischemic necroses and collapse of hepatic lobes with the development of connective tissue septa. It is known that the liver performs a number of functions to ensure normal activity of the human body -excretory, digestive, energy, [19] .
According to I.R. Popova, the prevalence of fatty hepatosis and non-alcoholic steatohepatitis (NASH) is growing with the increase in the body mass index (BMI). In obese patients hepatic steatosis occurs 2.7 times more frequently than in patients with normal BMI, and NASHeight times more frequently [20] .
The notion of abdominal obesity (AO) is introduced which, according to NCEP ATP III, was diagnosed in case of a waist measurement (WM) of more than 102 cm in males and more than 88 cm in females. Abdominal obesity contributes to fast progression of cardiovascular diseases, their severity and incidence of complications. According to INTERHEART study, abdominal obesity is an independent risk factor of myocardial infarction [21] .
Abdominal overweight type is an independent risk factor of NAFLD. Progressive weight gain contributes to a faster development of NAFLD; thus, the risk of its development increases by 45% if a person gains 2 kg or more a year.
Every 2.5 cm of waist measurement increases blood pressure by 10%, total cholesterol by 8% and triglycerides 18%, and decrease high-density lipoproteids (HDLP) by 15% [12] .
For many years, liver biopsy has been the "golden standard" of NAFLD diagnostics. This methods allows assessing pathognomonic morphological symptoms, determine structural organ changes and the degree of connective tissue development [22] . But this method has a number of disadvantages, among which the first is its invasiveness. Biopsy is associated with a risk of complications with the most common being abdominal pain (approximately in 25% of cases). The share of complications requiring hospitalization or extended in-patient care is 1-3%. According to the analysis of the structure and aetiology of biopsy-associated complications, the incidence of complications increases
proportionally to the amount of biopsy material and the number of sessions and when biopsy is performed in patients with relative counter-indications [23] .
Other limitations include the so called sampling error. It means that, if there is no evidence of pathological processes in the biopsy material, the probability of a hepatic disease cannot be completely ruled out. On the one hand, the possibility of this error is explained by the fact that the morphologist assesses the nature and intensity of hepatic changes based on a fragment of hepatic tissue containing at least 3-4 portal tracts. On the other hand, the sampling error is due to the heterogeneity and different intensity of hepatic changes. In its turn, it results in a low representativeness of biopsy findings [24] .
Besides, the interpretation of morphological biopsy findings largely depends on the morphologist's experience so the subjective factor cannot be eliminated, either. Thus, both an underestimation of the existing changes and a hyperdiagnosis of certain liver diseases and fibrosis grades can take place during liver biopsy examinations.
Other limitations include high costs of the procedure, and impossibility to perform frequent repeated biopsies; therefore, this method cannot be used for assessing chronic liver disease progression and therapy efficiency. Furthermore, there is a number of biopsy counter-indications, including coagulopathy, haemangioma or liver echinococcosis [24] .
According to 2016 clinical recommendations of EASL- [29] .
The most accessible non-invasive diagnostic technique of liver steatosis is abdominal ultrasound scanning. Ultrasound is the preferable technique for the first-line NAFLD diagnosis because it provides additional diagnostic data. It has A1 strength of recommendation [26] . The main diagnostic criteria include increased liver size, increased echogenicity, flattening of the vascular pattern [27] . According to the literature, sensitivity and specificity of this technique is 60-94 and 88-95%, respectively [28] .
According to the authors of EASL-EASD-EASO 2016 recommendations for the diagnosis and treatment of NAFLD, the most reliable scales for assessing steatosis are fatty liver index (FLI), SteatoTest and NAFLD liver fat score.
Their external validity was confirmed among the general population and among obese patients; they also predict outcomes and mortality rates associated with metabolic, hepatic, and cardiovascular conditions with different degrees of accuracy. These rates are closely linked with IR and reliably predict steatosis [29] .
According to S. McPherson et al., the predictive value of the negative AST/ALT test result is 93%, which leads to a conclusion that this index can rule our severe fibrosis in patients with NAFLD with a high degree of confidence [30] .
Besides, several authors have offered several other quantitative indices for the estimation of NAFLD and fibrosis risks:
1. HAIR index taking into account hypertension, ALAT > 40 IU/L and IR. It has 80% sensitivity and 89% specificity [31] .
2. BAAT index taking into account BMI >28 kg/m², age >50
years, ALT and TG increase level [32] .
3. Forns index taking into account age, platelet count, GGTP, and cholesterol [33] .
4. Bonacini index -platelet count, ALT/AST ratio, INR [34] .
5. FIB4 index (ALT, AST, platelet count, age) [35] .
6. APRI index (AST to platelet count ratio) [36] .
According to Shimada M. et al. (2007) , almost all patients with NAFLD and overweight had symptoms of IR assessed through the insulin resistance index HOMA-IR [38] . As a non-invasive marker during the measurement of IR quantitative characteristics at the background of the activity level of the synthesis of adiponectin, HOMA-IR and collagen 4, sensitivity and specificity were 94% and 74% [38] .
In an attempt to build an optimum predictive model us- and specificity of this method during the NASH diagnostics was 86% and 90% respectively; however, these findings need to be confirmed in larger independent studies [41] . 
NAFLD treatment principles
The pandemic of obesity and diabetes mellitus along with with impaired glucose tolerance, especially in those with BMI >25 kg/m2 [50] . The data collected over many years caused the American Diabetes Association recommends prescribing metformin to all patients with pre-diabetes (impaired glucose tolerance and impaired fasting glucose), especially those with BMI ≥25 kg/m2, aged below 60 years old and females with prior gestation diabetes [51] .
Studies of several authors showed that a significant decrease in IR and hepatic transaminases and improvement of metabolic values were reported at the background of metformin therapy combined with hypocaloric diet for 6 months in patients with metabolic syndrome (MS) and NAFLD [3] . However, in a number of studies, metformin therapy in NASH was not accompanied by histological improvement which caused its role in clinical recommendations to be adjusted [52] .
Experts of the American Association for the Study of Liver
Diseases use statins and vitamin Е for the treatment of
NAFLD. The efficiency of antioxidants and cytoprotectors
for NASH is questioned [53] ; however, the findings of the PIVENS study on the efficiency of vitamin E confirm histological shifts towards decreased intensity of inflammation in hepatocytes in patients with NASH [54] . It was shown that in patients without DM with histologically verified NASH, long-term therapy with vitamin E 800 mg/day has a pronounced antioxidant action and leads to both histological and clinical laboratory improvement. Vitamin Е is not recommended for the treatment of NASH in patients with DM, confirmed NAFLD biopsy, steatohepatitis with progression to liver cirrhosis and cryptogenic cirrhosis [48] .
According to M. Ekstedt (2007) , patients with NAFLD who received statins demonstrated more intensive histologically confirmed reduction of liver steatosis as compared to patients with NAFLD who did not receive statins [55] . According to C. Argo (2008) , statins influence the level of gene expression responsible for fibrosis progression and the rate of reparation processes [56] .
A decrease in the concentration of TNF-α, IL-6, and creactive protein (CRP) served as the mechanism of beneficial effect of statins on the development of NASH. It is believed that statins may affect angiogenesis, growth of tumour cells, apoptosis and metastatic activity, which can prevent the development of hepatocellular carcinoma [57] .
According to V.T. , for administration of statins is not dependent on the presence of NAFLD and obesity, elevated liver transaminases observed in 0.5-2% of cases, depending on the dose and drug is transient [57] , and in patients with initially increased levels of transaminases (AST>40 IU/l, ALT>35 IU/l) the intake of statins did not produse their increase. According to AGC and AGA recommendations, these drugs cannot be used to specifically treat NASH [48] .
Medicinal agents from the incretin group have certain po- UDCA has an anti-inflammatory effect mediated by a decrease in anti-inflammatory cytokines [62] . However, due to the lack of evidence the Association does not recommend prescribing ursodeoxycholic acid agent to patients with NAFLD and NASH [48] .
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The liver plays an important role in the development of by metabolic impairments [43] .
CONCLUSIONS
Non-alcoholic fatty liver disease is a very common disease among the world's population. Most often, NAFLD is associated with visceral obesity, which leads to an increased risk of cardiovascular disease in these patients.
Also, it is clear that in the majority of the patients, NAFLD is characterized by a long, stable asymptomatic course. In turn, the timely diagnosis can significantly improve the patient's quality of life and prevent fatal complications.
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